Cogent Biosciences, Inc. (COGT): R&D Expense
$269.78M
Year ended 2025-12-31
$290.72M
Trailing 12 months to 2026-06-30
+30.4%
3-year compound annual growth
+60.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $269.78M | +16.0% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $232.66M | +33.9% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $173.75M | +42.9% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $121.63M | +117.5% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $55.91M | +117.2% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $25.74M | -41.1% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $43.71M | +14.2% | 2021-03-16, From 2019-01-01 |
| 2018-12-31 | $38.28M | +28.3% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $29.83M | n/a | 2019-03-28, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | 2025-12-31 | $269.78M | +16.0% |
| Praxis Precision Medicines, Inc. (PRAX) | 2025-12-31 | $267.12M | +75.3% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $451.95M | -10.8% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $338.93M | +42.3% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $125.90M | +84.1% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.43M | +5.2% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $186.18M | +32.4% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $160.22M | +69.9% |
Compare COGT, PRAX, BBIO, VRDN side by side · Screen every company in Pharmaceutical Preparations ↗